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In the United States, the rate of induction of labor (IOL) has
significantly increased from 9% in 1990 to just over 23% in
2012.1 There are many medicinal and mechanical options
available to induce labor, including dinoprostone inserts,
misoprostol, balloon catheters, and oxytocin. The goal in
selecting which agent and route to use should depend on the
safety profile and efficacy. Additionally, the woman’s pre-
ference should be considered.2
Although used off-label, misoprostol is frequently used in
obstetrics for IOL. Its safety and efficacy have been exten-
sively supported by research.2–4 The oral and sublingual
routes are easily administered and considered less invasive.
However, they are often associated with more adverse side-
effects, such as chills, nausea, vomiting, and diarrhea, when
compared with the vaginal route.5 The oral and sublingual
routes have the shortest time to peak serum concentration
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Abstract Objective To survey obstetrical provider preferences regarding use of misoprostol for
induction of labor (IOL).
Methods An anonymous 25-question survey was distributed at an American College
of Obstetricians and Gynecologists (ACOG) joint District V and VII Meeting in 2014 to
obstetrics providers. The same survey was sent electronically to local providers. A
separate survey was emailed to the labor and delivery nurses at two of the teaching
hospitals in Indianapolis. The surveys queried provider demographics, dosing practice
for misoprostol, opinions regarding different dosing strategies, and instructions on
buccal administration.
Results A total of 113 (46.5%) providers responded. Of these, 92.9% usedmisoprostol
for IOL, 73% preferred the vaginal route, 20% preferred buccal administration, and 7%
oral administration. Only resident physician and midwife providers endorsed buccal
route preference. Being a midwife independently predicted a preference for using
buccal misoprostol (odds ratio [OR]: 125.8, 95% confidence interval [CI]: 7.9–1992.3).
Additionally, 44 nurses completed the survey regarding administration techniques of
buccal misoprostol. Also, 54.5% of nurses correctly instructed their patients on buccal
administration techniques.
Conclusion Although not extensively studied, one-fifth of providers, particularly
nurse midwives, prefer buccal administration of misoprostol for IOL. The majority of
nurses correctly administered buccal misoprostol. There may be a need for further
study and education about buccal administration of misoprostol for IOL.
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and the highest peak serum concentration,6 which may
contribute to these adverse side-effects. The vaginal route
is typically more uncomfortable for the woman and usually
requires a provider to administer; however, it has fewer side-
effects due to its longer time to peak concentration and lower
peak concentration.7 Vaginal misoprostol has a higher bioa-
vailability (a greater area under the concentration–time
curve) that contributes to its longer duration of action
than the oral or sublingual routes requiring less frequent
dosing.6 Clinically, we have noticed a trend toward more use
of buccal misoprostol for IOL, even though there are few data
comparing the different routes of administration.8
The objective of this study was to survey obstetrical
providers’ preferences regarding the route and dosing of
misoprostol as an induction agent for a live, singleton,
term fetus. Additionally, this study sought to evaluate pro-
vider thoughts and comfort level with buccal administration
of misoprostol. A secondary objective was to assess the
instructions given by labor and delivery nurses regarding
buccal misoprostol.
Materials and Methods
This study was approved by the Indiana University Institu-
tional Review Board (IRB).
Survey of Providers
The study population consisted of obstetric providers in
attendance at the April 2014 American College of Obstetri-
cians and Gynecologists (ACOG) combined Annual District V
and VII Meeting in Indianapolis, IN, and faculty, residents,
and nursing staff affiliated with the Indiana University
School of Medicine (IUSM). Study data were collected and
managed using the Research Electronic Data Capture (RED-
Cap) software hosted at the Indiana University. REDCap is a
secure, web-based application.9
The survey to the providers consisted of 25 questions, 7 of
which were questions on demographics. A mid-level provi-
der was defined as a nurse practitioner, certified nurse
midwife, or a physician’s assistant. Most questions were
single-selection answer choices with occasionally free text
answers (see ►Appendix A ). For the electronic version, if a
provider answered “no” to the question “As part of your
normal practice, do you use misoprostol for induction of
labor of a live fetus?” then the REDCap logic commands
would skip to the applicable questions and terminate the
survey early. The survey questions were developed with
experts in survey methodology but were not formally vali-
dated. Theywere pilot testedwith a small group of providers
and wording revised to the final form in ►Appendix A .
Four weeks prior to the meeting, the electronic version of
the survey was emailed to the obstetric providers associated
with IUSM as a convenience sample. There were instructions
to complete the survey at first attempt, although due to the
anonymity of the process, duplications were unable to be
detected. After approved by the District V Advisory Council,
the identical paper survey was distributed to those in
attendance at the District Meeting as a voluntary and anon-
ymous survey with instructions to return it to a collection
container. No surveyswere electronically submitted after the
paper surveys were distributed.
Survey of Nursing Staff
Nurses were surveyed if they were associated with the IUSM
obstetrics and gynecology residency program and worked at
either Eskenazi Hospital orMethodistHospital in Indianapolis.
This shorter survey consisted of six questions that focused on
theadministrationofbuccalmisoprostol (seeAppendixB). The
nurseswereemailed througheachhospital’s list-serve, and the
data were collected with the REDCap software.
Analysis
Collated surveys were summarized with descriptive statis-
tics. Comparisons between physician andmidlevel providers
were performed with chi-squared test for discreet variables
and t-tests for continuous variables as applicable.
Results
Provider Survey
At the ACOG District Meeting, 177 people were documented
to be in attendance, of whom, 124 were physicians/obstetric
providers. Of the 106 paper surveys distributed at this
meeting, 60 surveys were returned (56.6%), all completed
by the providers. Additionally, 137 email solicitations were
sent yielding 53 surveys submitted electronically (38.7%).
Thus, there were a total of 113 provider surveys completed
for an overall response rate of 46.5%.
Of the providers surveyed, 96 (85%) were physicians, 14
(12%) were mid-level providers, and 3 selected as “other”
(left blank or stated that they no longer practiced
obstetrics, ►Table 1) Of the physicians, 39 (41%) were still
in training, either residency or fellowship. A total of 93 (97%)
physicians were trained in obstetrics and gynecology. The
remaining physicians were either family practitioners
(n ¼ 2) or were double boarded in both (n ¼ 1). Half of the
providers (50.4%) stated they were in academic medicine,
24.5% in private group practice, 11.8% still in training, 6.2%
associated with a hospital-owned group practice, 2.7% were
solo practitioners, and 0.9% worked for a government-af-
filiated hospital. Seventy percent of the participants were
females (►Table 1). Most respondents (67%) had been in
practice < 10 years or were in residency.
The majority of participants responded that they use
misoprostol as an agent of induction of labor (92.9%). Of
the eight providers who did not use misoprostol, reasons
given included “no longer practicing obstetrics,” “preferring
other agents like a Foley bulb,” “it is not FDA approved,” and
“the nurses are uncomfortable.” Most providers (73%) pre-
ferred to administer misoprostol vaginally, with 20% re-
sponding that they preferred the buccal route, and 7%
preferred oral administration. No one endorsed preferring
the sublingual or rectal routes for labor induction. Of those
who preferred the buccal route, half weremidlevel providers
and the other half were obstetrics and gynecology resident
physicians in varying years of training.
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The majority of providers (77%) routinely calculated a
Bishop score prior to starting an induction of labor, and of
those who did, a score of 6 to 8 was most often deemed
favorable to startoxytocin rather thanacervical ripeningagent
such as misoprostol. The majority (93%) selected a starting
dose ofmisoprostol at 25 µg for IOL. The rate of beginningwith
a dose of 25 µg was somewhat lower for those preferring the
oral route (71 vs. 95% each for vaginal and buccal, p ¼ 0.12).
Twenty-ninepercentof thoseendorsing theoral routebeganat
a dose of 50 µg. When asked if they would increase the
subsequent dose of misoprostol, 52% considered doing so
(either routinely or if there was no response from the initial
dose). Of these, all opted for a 50 µg dose to be given either
vaginallyorbuccally. Themaximumcomfortablesingledoseof
misoprostol tobegivenwasnotedas50µgby75%ofproviders;
however, eight individuals felt comfortable administering 100
to 200 µg with varied routes of administration (oral, buccal,
and vaginal). A total of 92.3% providers responded that they
administered misoprostol every 4 hours as per ACOG guide-
lines.3 Three responded that an hourly dose was used; these
providers administered misoprostol orally at 25 µg as the
starting dose. The mean total maximum number of doses of
misoprostol that providers felt comfortable administeringwas
5.8; however, 30% did not have a cutoff. When asked if there
was a maximum total cumulative dose of misoprostol, provi-
ders felt comfortableadministering themediandoseas250µg,
but 56% of providers did not have a maximum. For those who
used both vaginal and buccal administration of misoprostol,
42.6% used the same dose for each route, whereas 11.9%
increased the dose when given buccally.
Whenquestionedaboutwhich routewasmoreeffective, 5%
thought the buccal route was more effective than the vaginal
route, 36% considered them equal, and 24% thought the buccal
route was less effective; the remaining 34% responded that
theywere unaware of any studies comparing the effectiveness
between the two routes. According to the survey, the most
persuasive sources to change a provider’s use of buccal mis-
oprostol for IOL would have to come from the ACOG practice
bulletins (78%), peer-reviewed journal articles (53%), or data
presented at a conference (46%). Additionally, 80% of providers
said they would consider enrolling patients in a study that
used buccal misoprostol for IOL at term.
Table 1 Comparison of characteristics of providers preferred route of misoprostol administration
Characteristic Overall
(n ¼ 113)
Prefer vaginal
(n ¼ 75)
Prefer buccal
(n ¼ 20)
Prefer oral
(n ¼ 7)
p-Valuea
Age category 0.07
< 30 y 23 (21%) 14 (64%) 7 (32%) 1 (4%)
31–40 y 43 (39%) 26 (63%) 11 (27%) 4 (10%)
41–50 y 19 (17%) 15 (88%) 2 (12%) 0 (0%)
51–60 y 14 (13%) 9 (82%) 0 (0%) 2 (18%)
61–70 y 10 (9%) 10 (100%) 0 (0%) 0 (0%)
Gender (female) 76 (70%) 46 (62%) 19 (95%) 5 (71%) 0.018
Gender (male) 37 (30%) 28 (90%) 1 (3%) 2 (6.5%)
Type of practitioner <0.001
Physician 96 (85.0%) 73 (83%) 10 (11%) 5 (6%)
Midlevel provider 14 (12.4%) 1 (8%) 10 (77%) 2 (15%)
Other 3 (2.6%) 1 (100%) 0 (0%) 0 (0%)
In practice <10 y 73 (67%) 46 (67%) 18 (26%) 5 (7%) 0.042
In practice 10 y 36 (33%) 28 (90%) 2 (6.5%) 1 (3%)
Practice setting 0.008
Academic/University 56 (51%) 36 (67%) 16 (30%) 2 (4%)
Solo practice 3 (2.7%) 1 (100%) 0 (0%) 0 (0%)
Group private practice 27 (24.5%) 22 (92%) 1 (4%) 1 (4%)
VA/Government affiliate 1 (1%) 0 (0%) 0 (0%) 1 (100%)
Resident physician 13 (11.8%) 9 (69%) 2 (15%) 2 (15%)
Otherb 10 (9.1%) 6 (75%) 1 (12.5%) 1 (12.5%)
Abbreviation: VA, veteran affairs.
Note: Results are presented as n (%).
ap-Values for comparisons are between the three preference groups.
bOther category included mostly providers who commented that they were in a hospital owned-practice or worked as hospitalists/laborists.
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Of the providers who administered buccal misoprostol,
themajority (55.6%) gave instructions to the patients to keep
themedicine in their cheek until completely dissolved versus
moving it around if not dissolved (3.7%), swallowing it if not
dissolved (24.1%), or no specific instructions given (16.7%).
►Table 1 also displays the characteristics of providers
who endorsed preference to start induction with vaginal,
buccal, or oralmisoprostol. Preference for buccalmisoprostol
was associated with being female, a midlevel provider, in
practice < 10 years, and at an academic/university-affiliated
practice. Female providers more often preferred to begin
inductions with buccal misoprostol compared with male
providers (34.3 vs. 9.7%, p ¼ 0.018). In a multivariable logis-
tic regression controlling for gender, age category, type of
practitioner, and practice setting, only being a midlevel
provider predicted a preference for starting inductions
with a nonvaginal route of misoprostol (OR: 125.8, 95% CI:
7.9–1992.3).
Nurse Survey
There were 44 responses to the nursing survey of the total
pool of 179 nurses approached (response rate was 24.6%,
although we were unable to verify if all nurses actually
received and read the email). The questions focused on the
instructions given to the patientswhen administering buccal
misoprostol. Among the nurses surveyed, 41 (93.2%) had
previously administered buccal misoprostol; the surveys
from the other 3 nurses were left blank. All but two nurses
instructed the patients to place themedication in the correct
anatomical location between the lip andmucosa of the gums.
The remaining two nurses indicated that they gave the
medication sublingually. The majority of nurses (54.5%)
instructed patients to wait for the medicine to completely
dissolve; one recommended massaging the medicine in the
check. If instructionswere given involving time, a range from
20 to 60 minutes was recommended before either swallow-
ing or massaging the pill.
The majority of nurses reported receiving instructions on
buccal administration from another nurse (50%), a physician
(33%), or from a variety of other sources including reading it
on their own (7.5%) in nursing school (5%), from a midwife
(2.5%), or fromwritten directions on the order (2.5%). Of note,
the twonurses that incorrectly administered themisoprostol
sublingually reported learning their technique from a phy-
sician and from the written order.
Discussion
Our study revealed that most of the practitioners surveyed
utilizedmisoprostol for IOL of a term, live, singleton fetus and
preferred the vaginal route of administration. The dose and
timing of misoprostol was consistent with the practice
trends and guidelines from ACOG of 25 µg doses every 4
hours.3 Additionally, our results were similar to results from
a surveyof providers in Switzerland.10 That surveyalso found
that the most frequent route of administration was intrava-
ginal (86%) but that most providers preferred a 50 µg dose
(94%) with similar dosing intervals.10 It was interesting that
the only providers who completed the survey that used the
buccal route of administration were mid-level providers or
physicians in their residency training. Also, being amid-level
provider independently predicted a preference for the buccal
route, controlling for age, practice setting, and gender. One
possible explanation for this is the appeal of the patient for
the less-invasive route; most mid-level providers participat-
ing in the study were certified nurse midwives who often
care for patients who prefer minimal interventions and
limited cervical exams making the buccal route of drug
administration an appealing option. Another possible ex-
planation is that there was a recent education session from a
guest lecturer discussing the advantages of buccal adminis-
tration of misoprostol for miscarriage management and IOL
at the IUSM. The survey in Switzerland only questioned
obstetricians.10
From the study results, most participants stated that they
were unaware of the evidence regarding the use of buccal
misoprostol for induction of labor. To our knowledge, there
are only limited data on the topic. One randomized control
trial compared buccal to vaginal misoprostol and one Co-
chrane Review combined buccal and sublingual study.8,11
However, there are multiple studies supporting efficacy and
safety of sublingually administered misoprostol when com-
pared with the vaginal and oral routes for IOL.12–16
The buccal mucosal administration ofmisoprostol is a less
studied route in obstetrics, but it has some favorable proper-
ties. Similar to the oral and sublingual routes, it is easily
administered and minimally invasive. Similar to the vaginal
route, it has a longer time to peak serum concentration and
lower peak serum concentration.6
The limitations of the current study include those com-
mon to survey studies.We experienced a low rate of return of
completed paper surveys, although our return rate is on par
with many other provider practice surveys. One explanation
for the low return of provider surveys at the District Meeting
may be due to the high proportional attendance of nonob-
stetrical subspecialists (i.e., gynecology, oncology, and
female pelvic medicine) no longer practicing obstetrics.
Additionally, medical students present at the meeting
received the survey included in the meeting materials but
were instructed not to participate. Another possible expla-
nation is the providers associated with IUSM most likely
completed the emailed electronic version prior to receiving a
paper version at the ACOG District Meeting, which could
account for some of the 46 paper surveys not returned. We
were unable to control for duplicated survey completions;
however, we did instruct providers at the meeting who may
have already completed the survey to not complete attempt
it again. The study was also limited in its generalizability in
that the District Meeting took place in Indiana, potentially
leading to an over-representation of providers from the
Midwest. To improve generalizability, we evaluated the
feasibility of distributing the survey through the ACOG
Collaborative Ambulatory Research Network, through the
ACOG list-serve, or via residency program coordinators but
were concerned with potentially lower response rates with
these methods.
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Additionally, the survey of nurses was local to the hospi-
tals associated with the department. Thus, these results may
not be generalizable. Repeating the survey to a national office
may be needed. As the surveys asked different questions to
the two groups, we were unable to compare the results
between the physician and nursing practices.
The results from this study suggest that most obstetrical
providers are comfortable with the use of misoprostol for
induction of labor of a live, term fetus. Although vaginal
misoprostol is currently the favored route, one fifth of the
providers surveyed preferred the buccal route. The prefer-
ence for the buccal routewas particularly seenwithmidlevel
providers. As there are little data directly comparing vaginal
to buccal administration of misoprostol for IOL, direct com-
parison of clinical trials is required. These trials should
include patient satisfaction measures so that if clinical and
adverse event findings are equivalent, patient preference
may help guide care. According to our results, themajority of
providers that participated in this survey would be comfor-
table involving their patients in such a study.
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